Comparative study between weekly dose of 50mg of Mifepristone and daily dose of 25 mg Mifepristone in medical management of uterine fibroid
Phase 3
- Conditions
- Health Condition 1: N938- Other specified abnormal uterine and vaginal bleeding
- Registration Number
- CTRI/2022/02/040442
- Lead Sponsor
- Dr Subhasri S
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Women of age group 30-45
Women with symptomatic fibroid
Fibroid size 3-5cm
Without endometrial hyperplasia
Exclusion Criteria
Uterine size more than 12weeks
Associated cervical or tubal lesions
Pregnancy
Fibroid with severe anemia
Hepatic and renal dysfunction
Endometrial hyperplasia
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method